Mapping lymph nodes in colon cancer using fluorescent dye

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of using indocyanine green (ICG) dye to visualize lymph nodes draining from colon carcinoma during surgery. Participants diagnosed with adenocarcinoma of the colon will receive ICG injections prior to surgery, allowing for the identification of lymph nodes that may be outside the standard resection lines. The study aims to document the locations of these nodes and correlate their fluorescence with cancer positivity. This approach could enhance surgical precision and potentially improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically diagnosed carcinoma of the ascending, transverse, descending or sigmoid colon.

Exclusion Criteria:

* not wanting to participate
* other carcinoma then adenocarcinoma
* endoscopic marking not possible

Where it's running

• University of Hamburg Medical Institutions
  Hamburg, Germany Recruiting

Study contacts

• Principal investigator: Daniel Perez, Prof. Dr. — Dept of General Visceral and Thoracic Surgery
• Study coordinator: Katharina L Lucas, MD
• Email: katharina.lucas@uni-wh.de
• Phone: +4915779600815

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zanidatamab given before surgery for HER2-positive colon or rectal cancer

  This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.

  Recruiting at 4 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07405476

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Phytocannabinoids to reduce chronic chemotherapy-related nerve pain in breast and colon cancer survivors

  This will test whether daily CBD or a combined THC:CBD treatment can reduce long-term nerve pain, tingling, and numbness in people who survived breast or colon cancer.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06731894

• Imaging study using two antibody fragments in patients with solid tumors

  This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.

  Recruiting Early Phase 1 Var2 Pharmaceuticals · Groningen, Provincie Groningen · NCT06645808

• Evaluating NRT6008 for patients with advanced pancreatic cancer

  This study is testing a new injection called NRT6008 to see if it is safe and effective for people with advanced pancreatic cancer that can't be removed by surgery.

  Recruiting at 6 sites Phase 1 Chengdu New Radiomedicine Technology Co. LTD. · Zhengzhou, Henan and 5 other locations · NCT06278454

• Chemoradiation for vulvar cancer patients with large sentinel node metastasis

  This study is testing if combining chemotherapy and radiation can be a safer and more effective treatment for women with early-stage vulvar cancer who have larger cancer spread in their lymph nodes, instead of having surgery.

  Recruiting at 27 sites Phase 2 University Medical Center Groningen · Orange, California and 26 other locations · NCT05076942

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.